Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis
|
|
- Kory Owen
- 5 years ago
- Views:
Transcription
1 ARTHRITIS & RHEUMATISM Vol. 54, No. 5, May 2006, pp DOI /art , American College of Rheumatology Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis Samy Suissa, Marie Hudson, and Pierre Ernst Objective. Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently. To assess this risk, we conducted a populationbased epidemiologic study. Methods. A cohort of 62,734 patients with RA to whom a DMARD had been dispensed between September 1, 1998 and December 31, 2003 was formed using the PharMetrics claims database. A nested case control design was used, in which each case of serious ILD requiring hospitalization was matched to 100 controls according to age (calendar time) and equal or greater duration of followup, to estimate adjusted rate ratios (RRs) of serious ILD associated with DMARD use. Results. There were 74 cases of serious ILD, which corresponds to a rate of 8.1 per 10,000 patients per year. The risk of ILD was increased with the use of leflunomide (adjusted RR 1.9 [95% confidence interval (95% CI) ]). Among subjects with no previous methotrexate use and no history of ILD, the risk associated with leflunomide treatment was not elevated (RR 1.2 [95% CI ]), but it was elevated among the remaining subjects (RR 2.6 [95% CI ]). Patients with a history of ILD were twice as likely to have been prescribed leflunomide as any other DMARD. Supported by grants from Sanofi-Aventis and the Canadian Institutes of Health Research. Dr. Suissa is recipient of a Distinguished Investigator award from the Canadian Institutes of Health Research. The McGill Pharmacoepidemiology Research Unit is funded by infrastructure grants from the Fonds de la Recherché en Santé du Québec. Samy Suissa, PhD, Marie Hudson, MD, MPH, Pierre Ernst, MD, MSc: McGill University Health Centre, Montreal, Quebec, Canada. Dr. Suissa has received consulting fees or honoraria (less than $10,000 per year) from Bristol-Myers Squibb and Sanofi-Aventis. Address correspondence and reprint requests to Samy Suissa, PhD, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Quebec H3A 1A1, Canada. samy.suissa@clinepi.mcgill.ca. Submitted for publication June 2, 2005; accepted in revised form January 31, Conclusion. The reports of ILD associated with leflunomide use are likely the result of channeling of high-risk patients to leflunomide treatment, particularly those with a history of methotrexate use or preexisting ILD. Patients with no history of ILD and no previous methotrexate use show no excess risk of developing ILD with leflunomide treatment. Leflunomide, a disease-modifying antirheumatic drug (DMARD), has been available in the US since 1998 for the treatment of active rheumatoid arthritis (RA) (1). Soon after its launch in Japan in 2003, 16 cases of interstitial pneumonitis were reported in that country, of which 5 resulted in death; several of the 16 patients had preexisting lung disease (2). A subsequent Japanese study reported 26 cases of leflunomide-associated acute lung injury (3). It is unclear whether leflunomide is directly related to the occurrence of such lung toxicity or whether other factors, including channeling bias, may explain this. Commonly used DMARDs, in particular, methotrexate, have been associated with pulmonary toxicity (4,5). Preexisting lung disease has also been reported to be a risk factor for the development of methotrexate pneumonitis (5). We thus conducted a large-scale cohort study to assess the risk of interstitial lung disease (ILD) associated with the use of leflunomide. We also assessed whether this risk is modified by a history of lung disease and of methotrexate use. Finally, we investigated the possibility of channeling bias by assessing whether patients with lung disease were more likely to be prescribed leflunomide when it became available. SUBJECTS AND METHODS Role of the funding source. Sanofi-Aventis made all arrangements to acquire the databases examined in this study. The authors independently designed the study, analyzed the data, interpreted the results, and wrote the manuscript. The 1435
2 1436 SUISSA ET AL Figure 1. Flow chart showing the selection of subjects from the PharMetrics database who were evaluated in the case control study assessing the risk of interstitial lung disease (ILD) and in the case control analysis of the determinants of channeling to the newer disease-modifying antirheumatic drugs (DMARDs). RA rheumatoid arthritis. manuscript was reviewed and approved by Sanofi-Aventis prior to submission. Data sources. The study was performed using the PharMetrics Patient-Centric Database (6). This database consists of standardized information on claims data, including physician visits, dispensed prescription medications, and hospitalizations, from more than 75 different managed care organizations and currently encompasses data for more than 55 million unique patients. This database has been used previously to assess the hepatic and cardiovascular effects of DMARDs (7,8). Study populations. We first identified the source population of all subjects with at least 1 diagnosis of RA (International Classification of Diseases, Ninth Revision [ICD-9] code 714) for an inpatient or an outpatient encounter between January 1995 and December 2003 (Figure 1). We formed a DMARD-treated cohort that was defined as all subjects who received at least 1 prescription for a DMARD on or after September 1, 1998, the month leflunomide was approved in the US. The DMARDs included leflunomide, methotrexate, all biologic agents, gold compounds, antimalarial drugs, minocycline, penicillamine, sulfasalazine, and cytotoxic agents. Cohort entry was defined as the date of the first such DMARD prescription. To avoid excluding subjects with fewer than 12 months of eligibility in the health insurance plan prior to cohort entry, all such subjects had their cohort entry date moved forward in time and redefined as the first prescription for a DMARD after 1 year of eligibility in the database. Accordingly, subjects who after this 1-year shift forward had no prescriptions for a DMARD were excluded. All subjects were tracked from cohort entry until the earliest of the following: the date of termination of enrollment in the health plan, the date of death, the end of the study period (December 31, 2003), or the date of the outcome of interest, namely, ILD (defined below). Subjects with the outcome of interest during the 1-year period prior to cohort entry were excluded. Subjects were 18 years of age or older at cohort entry. To address channeling bias, we identified all subjects from the source population who received a prescription for a DMARD between September 1, 1998 and December 31, Among those who received leflunomide or a biologic agent during this period, the first prescription of either of these 2 drugs was taken as the index prescription. The remaining subjects were divided into 2 groups: those who took only methotrexate during the observation period and all other subjects. For these 2 groups, a DMARD prescription was selected at random among all DMARD prescriptions dispensed during the observation period and was taken as the index prescription. Subjects with fewer than 4 months of eligibility in the health plans prior to the index prescription were excluded. Outcome. Cases of probable drug-related ILD were identified from inpatient encounters as all subjects who were hospitalized with a first-time primary diagnosis of postinflammatory lung fibrosis (ICD-9 code 515), idiopathic fibrosing alveolitis (code 516.3), or other/unspecified alveolar pneumonopathies (codes and 516.9). As a sensitivity analysis, we expanded the case definition to include ILD identified from outpatient encounters as well as mention of the relevant codes as secondary diagnoses during inpatient encounters. Nested case control design. We used a nested case control approach within the DMARD-treated cohort. This approach allows one to deal with the complexity in the patterns of multiple drugs used to treat RA and varying durations of treatment without significant loss of power (9). For each case of ILD identified in the DMARDtreated cohort, we randomly selected 100 controls from the cohort after matching for age (within a year) and the date of cohort entry. Controls also had to be at risk, that is, still in the cohort and without a diagnosis of ILD, on the day the case occurred. This date was designated as the index date for both cases and their matched controls. Measurement of exposure. For the primary analysis, all anti-ra drugs received during the year prior to the index date for both cases and controls were identified from dispensed prescription data. The DMARDs were divided into 4 categories: methotrexate, leflunomide, biologic agents (namely, infliximab, etanercept, adalimumab, and anakinra), and traditional DMARDs (namely, antimalarial agents, sulfasalazine, gold salts, minocycline, penicillamine, azathioprine, cyclosporine, and other cytotoxic agents). For the analysis addressing the channeling issue, the exposure of interest was the presence of an ILD diagnosis on
3 LEFLUNOMIDE USE AND PNEUMONITIS RISK IN RA 1437 any outpatient claim or as a secondary diagnosis on inpatient claims during the year prior to the index prescription. Covariates. The primary covariates included age, a matching factor, and sex, as well as all comorbid conditions based on diagnoses made during the year prior to the index date. These included cardiovascular disease, respiratory illness, diabetes mellitus, hypertension, hypercholesterolemia, cancer, gastrointestinal conditions, and central nervous system conditions. Other drugs prescribed for RA, such as glucocorticoids, nonsteroidal antiinflammatory drugs, and cyclooxygenase 2 inhibitors, were used as covariates. Respiratory disease codes that might signal the presence of ILD prior to cohort entry was defined as any diagnosis of postinflammatory lung fibrosis (ICD-9 code 515), idiopathic fibrosing alveolitis (code 516.3), and other or unspecified alveolar pneumonopathies (codes and 516.9) appearing on any outpatient claim or as a secondary diagnosis on inpatient claims during the year prior to cohort entry. Statistical analysis. Conditional logistic regression was used for all analyses of the nested case control study to estimate crude and adjusted odds ratios (ORs) of ILD associated with DMARD use during the year prior to the index date. Since these ORs are accurate estimators of the rate ratios (RRs), the latter term will be used throughout (10). All analyses were adjusted for the concurrent use of the other DMARDs, the other anti-ra drugs, as well as sex and comorbid conditions. To assess the effects of disease and treatment history on the RRs for leflunomide and methotrexate, we conducted analyses stratified by these factors. To assess the question of channeling to leflunomide, we compared the subjects with an index DMARD prescription of leflunomide, a biologic agent, or a traditional DMARD, with those with an index DMARD prescription of methotrexate only. We used unconditional logistic regression to estimate the OR adjusted for the use of other anti-ra drugs and for comorbidity factors during the year prior to the index prescription. RESULTS The source population consisted of 235,272 subjects with a diagnosis of RA between September 1, 1998, and December 31, The DMARD-treated cohort consisted of 62,801 subjects, of which 67 were excluded because they had the outcome during the year prior to cohort entry (Figure 1). The resulting 62,734 subjects in the study cohort were, on average, 54 years of age at cohort entry, and 75% were women. The majority entered the cohort with a methotrexate or a traditional DMARD prescription (78%). There were 74 subjects hospitalized because of ILD during followup. Of these, 43 had a diagnosis of postinflammatory pulmonary fibrosis, 8 had a diagnosis of idiopathic fibrosing alveolitis, and 23 had other alveolar pneumonopathies. With almost 91,000 person-years of followup, the rate of hospitalizations because of ILD in this cohort was 8.1 per 10,000 per year. The case group had more prior comorbidity and included more men than the control group (Table 1). The risk of ILD was increased with the use of leflunomide in the year prior to the index date (adjusted RR 1.9; 95% CI ) (Table 2). The increase was less and was not significant with the use of methotrexate (RR 1.4; 95% CI ). However, in stratified analyses, subjects who had not taken methotrexate during the year prior to cohort entry and who did not previously have ILD (37 cases and 4,259 controls) had an increased risk of ILD with methotrexate treatment (RR 3.1; 95% CI ) but not with leflunomide treatment (RR 1.2; 95% CI ). In contrast, among those who had previously taken methotrexate or who had a previous diagnosis of ILD (37 cases and 3,141 controls), the risk of ILD was elevated with leflunomide treatment (RR 2.6; 95% CI ) but was decreased with methotrexate treatment (RR 0.4; 95% CI ). For the sensitivity analysis, the case definition that included secondary discharge diagnoses identified 246 cases. The resulting adjusted RRs for ILD associated with methotrexate treatment (1.0; 95% CI ) and with leflunomide treatment (2.2; 95% CI ) remained similar to those from the study case definition. For the 1,073 cases in which outpatient diagnoses were also included, the adjusted RRs for ILD associated with methotrexate treatment (1.1; 95% CI ) and with Table 1. Baseline characteristics of cases hospitalized for interstitial lung disease (ILD) and their matched controls Cases (n 74) Controls (n 7,400) Age, mean SD years Followup, mean SD months Sex, % women Comorbidity in the year prior to cohort entry, % Cardiovascular diseases Ischemic heart disease Congestive heart failure 16 4 Cerebrovascular disease 9 4 Other cardiovascular disease Cardiovascular risk factors Hypertension Diabetes Hypercholesterolemia Other concurrent diseases Cancer Gastrointestinal diseases Central nervous system conditions Respiratory diseases Pneumonia/influenza 20 5 ILD (outpatient or secondary inpatient 24 2 diagnosis) Other lung disease 38 18
4 1438 SUISSA ET AL Table 2. Rate ratios of ILD associated with DMARD use in all subjects and in subjects stratified by previous methotrexate use and previous ILD during the year prior to entry into the cohort* DMARD use during the previous year Cases Controls Crude RR Adjusted RR (95% CI) All subjects 74 7,400 Methotrexate 41 3, ( ) Leflunomide ( ) Biologic DMARDs 13 1, ( ) Traditional DMARDs 35 2, ( ) Subjects with no previous methotrexate use and no 37 4,259 previous ILD Methotrexate 17 1, ( ) Leflunomide ( ) Subjects with previous methotrexate use or previous ILD 37 3,141 Methotrexate 24 2, ( ) Leflunomide ( ) *DMARD disease-modifying antirheumatic drug; RR rate ratio; 95% CI 95% confidence interval. Previous interstitial lung disease (ILD) was either an outpatient diagnosis or a secondary inpatient diagnosisduring the year prior to cohort entry. leflunomide treatment (1.5; 95% CI ) also remained comparable. To address the issue of channeling, we identified all 64,676 subjects who started on a DMARD on or after September 1, 1998 and had at least 4 months of data available prior to the index DMARD prescription (Figure 1). Patients with a previous diagnosis of ILD, whether hospitalized or not, were almost twice as likely to have been prescribed leflunomide relative to methotrexate (adjusted OR 1.9; 95% CI ) than patients with no such a diagnosis. These patients were also just as likely to have been prescribed biologic agents (OR 1.1; 95% CI ) or traditional DMARDs (OR 1.0; 95% CI ) compared with methotrexate. DISCUSSION In a large cohort of patients with RA treated with a DMARD, we observed an apparent 2-fold increased risk of ILD in patients treated with leflunomide compared with those not treated with leflunomide. However, the risk increase with leflunomide was restricted to patients with a history of methotrexate use or interstitial lung disease. There was no increase in the risk of ILD with leflunomide among the patients who had no previous methotrexate use and no interstitial lung disease prior to cohort entry. The increased risk of ILD in the patients treated with leflunomide appears to be due to a channeling bias, where patients with a history of ILD may have been preferentially prescribed leflunomide rather than methotrexate on the assumption that, in contrast to methotrexate, no lung toxicity was associated with leflunomide. Indeed, in subgroup analyses, among patients defined by the absence of a history of methotrexate use or ILD, there was no increased risk of ILD with leflunomide treatment, while the risk with methotrexate treatment was increased 3-fold. On the other hand, among patients with a history of methotrexate use or ILD, methotrexate treatment actually appeared to be highly protective (RR 0.4; 95% CI ) while the risk of ILD with leflunomide treatment was increased more than 2-fold. This channeling bias is further supported by the profile of patients who were prescribed leflunomide, where patients with a history of ILD were twice as likely to have been prescribed leflunomide as a first DMARD as compared with methotrexate, other traditional DMARDs, and biologic agents. Identifying a possible association between leflunomide and lung toxicity is difficult in part because interstitial pneumonitis is so rare. In clinical trials of leflunomide and in subsequent observational studies, the incidence has been too low to assess the risk with precision, or the estimated risk was not increased compared with other DMARDs (1,11 14). Large administrative databases have the advantage of allowing the identification of small risks that may have been missed in clinical trials. The current study is limited by the fact that it was exclusively based on computerized claims data. It was thus impossible to validate the endpoint of ILD. How-
5 LEFLUNOMIDE USE AND PNEUMONITIS RISK IN RA 1439 ever, we assumed that diagnoses recorded as primary diagnoses during the course of a hospitalization are more likely to be valid. A strength of the study is the inclusion of various populations in the cohort, encompassing Medicaid, Medicare, private health maintenance organizations, preferred provider organizations, and over 75 different managed care organizations, that make the findings generalizable. We conclude that patients treated with leflunomide who have no history of methotrexate use and no existing ILD carry no excess risk of ILD. The increase in the risk of ILD associated with leflunomide is restricted to the subgroup of patients with a history of methotrexate use or existing ILD, and this appears to be the result of a channeling bias. ACKNOWLEDGMENT We thank Dr. Juhaeri Juhaeri of Sanofi-Aventis for assistance with the database acquisition. REFERENCES 1. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001;44: McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363: Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2005;15: Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40: Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43: PharMetrics patient-centric database. Watertown (MA): Phar- Metrics, Inc Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. Newer disease modifying anti-rheumatic drugs (DMARDs) and the risk of serious hepatic adverse events in rheumatoid arthritis. Am J Med 2004;117: Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44: Suissa S. Novel approaches to pharmacoepidemiological study design and statistical analysis. In: Strom B, editor. Pharmacoepidemiology. New York: John Wiley & Sons; p Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Hagerstown (MD): Lippincott-Raven; Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003;48: Goldkind L, Simon LS. FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part III. Safety and efficacy update on leflunomide (Arava). URL: rheumatology.org/publications/hotline/0503leffda.asp?aud mem. 13. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004;31: Cannon GW, Finck BK, the Enbrel ERA Investigator Group, Simpson KM, the Leflunomide Investigators Group, Strand V. Methotrexate-induced pulmonary disease during treatment of rheumatoid arthritis in large clinical trials [abstract]. Arthritis Rheum 2000;43 Suppl 9:S341.
Proposed Retirement for HEDIS : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)
Proposed Retirement for HEDIS 1 2020 2 : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) NCQA seeks public comment on the proposed retirement of the Disease-Modifying Anti-Rheumatic
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationAn increasing number of reports are linking infections to
Research Reports Antibiotics in Primary Prevention of Stroke in the Elderly Paul Brassard, MD, MSc; Chantal Bourgault, PhD; James Brophy, MD, PhD; Abbas Kezouh, PhD; Samy Suissa, PhD Background and Purpose
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationCataracts are a major public health problem,
Eur Respir J 2006; 27: 1168 1174 DOI: 10.1183/09031936.06.00043005 CopyrightßERS Journals Ltd 2006 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts P. Ernst*,#, M. Baltzan*,",+,
More informationPROVIDER GUIDE Required information on targeted HEDIS and Part D measures
PROVIDER GUIDE Required information on targeted HEDIS and Part D measures Visit www.atriohp.com/star-ratings-program for full measure descriptions. Contact QI@atriohp.com with any questions. Adult Body
More informationThe New England Journal of Medicine LOW-DOSE INHALED CORTICOSTEROIDS AND THE PREVENTION OF DEATH FROM ASTHMA
LOW-DOSE INHALED CORTICOSTEROIDS AND THE PREVENTION OF DEATH FROM ASTHMA SAMY SUISSA, PH.D., PIERRE ERNST, M.D., SERGE BENAYOUN, M.SC., MARC BALTZAN, M.D., AND BING CAI, M.SC. ABSTRACT Background Although
More informationBRIEF REPORT. ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 7, July 2016, pp DOI /art VC 2016, American College of Rheumatology
ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 7, July 2016, pp 1588 1595 DOI 10.1002/art.39617 VC 2016, American College of Rheumatology BRIEF REPORT Intensification to Triple Therapy After Treatment With Nonbiologic
More informationINHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement.
INHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement. Samy Suissa, PhD, Marc Baltzan, MD, MSc, Richard Kremer, MD, Pierre Ernst, MD, MSc 26 METHODS Source of data We used
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationAnkylosing Spondylitis AS M45. Psoriatic Arthritis PSA L405, M070, M071, M073. Systemic Lupus Erythematosus SLE M320, M321, M328, M329
Appendix 1. Diagnosis codes according to International Classification of Disease version 10 (ICD 10) used to define rheumatoid arthritis (RA) and related diseases Diagnosis Abbreviation ICD 10 Rheumatoid
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationThe Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases
The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases SASHA BERNATSKY, TINA LINEHAN, and JOHN G. HANLY ABSTRACT. Objective. To examine the validity of case definitions
More informationEffectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials
Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials K. Martin 1, F. Bentaberry 2, C. Dumoulin 2, J. Dehais 2, F. Haramburu 1, B. Bégaud
More informationNo Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 4 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION No
More informationIntensification to triple therapy non-biologic disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States from 2009 to 2014
Brief Report DOI 10.1002/art.39617 Intensification to triple therapy non-biologic disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States from 2009 to 2014 Jeffrey A. Sparks,
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationReport on New Patented Drugs - Orencia
Report on New Patented Drugs - Orencia Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More information2017 Medicare STARs Provider Quality Indicators Guide
2017 Medicare STARs Provider Quality Indicators Guide Medicare STARs Rating Centers for Medicare & Medicaid Services (CMS) created a Five-Star Quality Rating System to help measure the quality in care
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More information2016 PQRS. Rheumatiod Arthritis Me asures Group. Measures. Reporting Instructions
Measures #108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy #128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan #131 Pain Assessment
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationBias and confounding special issues. Outline for evaluation of bias
EPIDEMIOLOGI BIAS special issues and discussion of paper April 2009 Søren Friis Institut for Epidemiologisk Kræftforskning Kræftens Bekæmpelse AGENDA Bias and confounding special issues Confounding by
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationErelzi (etanercept) Frequently Asked Questions
Erelzi (etanercept) Frequently Asked Questions 1. What is the funding status of Erelzi (etanercept)? Effective December 21, 2017, Erelzi (etanercept) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationJuvenile Idiopathic Arthritis and Risk of Cancer
ARTHRITIS & RHEUMATISM Vol. 62, No. 12, December 2010, pp 3776 3782 DOI 10.1002/art.27741 2010, American College of Rheumatology Juvenile Idiopathic Arthritis and Risk of Cancer A Nationwide Cohort Study
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationEffectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Machado et al. Arthritis Research & Therapy (2018) 20:60 https://doi.org/10.1186/s13075-018-1539-6 RESEARCH ARTICLE Open Access Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationTHIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY
TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY Samy Suissa McGill University and Jewish General Hospital Montreal, Canada ISPE mid-year meeting, Miami April 22, 2012 STATINS REDUCE: JAMA 2000: Fracture rate
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationRESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationLOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
More informationFriday and weekend hospital stays: effects on mortality
ERJ Express. Published on May 14, 2014 as doi: 10.1183/09031936.00007714 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Friday and weekend hospital stays: effects on mortality Samy Suissa 1,2, Sophie Dell Aniello
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationHEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS )
STARS MEASURES 2015 HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS ) Developed by the National Committee for Quality Assurance (NCQA), HEDIS is the most widely used set of performance measures
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationAdherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)
Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion
More informationName of Policy: Therapeutic Apheresis, with Extracorporeal Column Immunoadsorption and Plasma Reinfusion
Name of Policy: Therapeutic Apheresis, with Extracorporeal Column Immunoadsorption and Plasma Reinfusion Policy #: 010 Latest Review Date: December 2008 Category: Surgical Policy Grade: Effective March
More informationTwo-Year, Blinded, Randomized, Controlled Trial of Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Methotrexate
ARTHRITIS & RHEUMATISM Vol. 44, No. 9, September 2001, pp 1984 1992 2001, American College of Rheumatology Published by Wiley-Liss, Inc. Two-Year, Blinded, Randomized, Controlled Trial of Treatment of
More informationRequest for Special Authorization Enbrel
Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. Special Authorization requires that you request approval from Great-West Life for
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationDrug prescriptions (Pharm) Exposure (36/48 months)
ANNEX SECTION PART A - Study design: Figure 1 overview of the study design Drug prescriptions (Pharm) 2006-2010 Exposure (36/48 months) flexible time windows (e.g. 90 days) time index date (hospital discharge)
More informationRisk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study
Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j895 (Published
More informationClinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Kineret) Reference Number: CP.PHAR.244 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationAdherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritisvhe_
Volume 13 Number 6 2010 VALUE IN HEALTH Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritisvhe_764 805..812 Pengxiang Li, PhD, 1,2 Marissa A.
More informationActual use of medications is important for payers
ORIGINAL RESEARCH and Dosing for Plaque Psoriasis and Psoriatic Arthritis Machaon Bonafede, PhD, MPH; Derek H. Tang, PhD, BSPharm; Kathleen Wilson, MPH; Alice Huang, MS; David J. Harrison, PhD; and Bradley
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationAbatacept: first T cell co-stimulation modulator for severe active RA
Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method
More informationI nhaled corticosteroids are the treatment of choice in the
880 ORIGINAL ARTICLE Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma S Suissa, P Ernst, A Kezouh... See end of article for authors affiliations... Correspondence
More informationComments from Wyeth on the Assessment Report for the appraisal of Enbrel in RA General Comments
General Comments The TAR economic model is a complex model that attempts to reflect the multiple treatment options and pathways an RA patient can follow. This model demonstrates that it would be cost effective
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationPharmacy Medical Necessity Guidelines:
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationThe Efficacy and Safety of Leflunomide in Patients With Active Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 48, No. 6, June 2003, pp 1513 1520 DOI 10.1002/art.11015 2003, American College of Rheumatology The Efficacy and Safety of Leflunomide in Patients With Active Rheumatoid Arthritis
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationPharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)
Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationInhaled corticosteroids and the risk of a first exacerbation in COPD patients
Eur Respir J 2004; 23: 692 697 DOI: 10.1183/09031936.04.00049604 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 Inhaled corticosteroids and
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationIsoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
ORIGINAL ARTICLE 2017 Mar 13. [Epub ahead of print] Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More information